Search company, investor...

Eribis Pharmaceuticals


Seed | Alive

About Eribis Pharmaceuticals

Developer of drugs for the treatment of cardiovascular disorders, in particular acute myocardial ischemia, and also for surgical preconditioning. The company is based on research in the fields of peptide chemistry and pharmacology. Their main goal is to develop drug candidates to meet the market's demand for new and improved treatment in the field of cardio-protection.

Headquarters Location

Virdings Alle 32B

Uppsala, 754 50,


46 7 320 96 32 6

Missing: Eribis Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Eribis Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Eribis Pharmaceuticals Frequently Asked Questions (FAQ)

  • Where is Eribis Pharmaceuticals's headquarters?

    Eribis Pharmaceuticals's headquarters is located at Virdings Alle 32B , Uppsala.

  • What is Eribis Pharmaceuticals's latest funding round?

    Eribis Pharmaceuticals's latest funding round is Seed.

  • Who are the investors of Eribis Pharmaceuticals?

    Investors of Eribis Pharmaceuticals include Karolinska Development.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.